American participant takes part in medical trial by Anaconda Biomed within ATHENA research project
In a significant development for stroke treatment, Anaconda Biomed, a medical technology company, has announced the enrolment and treatment of the first U.S. patient in its ATHENA clinical trial. This trial is a global, randomised 327-patient pivotal study evaluating the safety and effectiveness of Anaconda's proprietary ANA Funnel Catheter.
Dr. Majidi, an Associate Professor of Neurosurgery, Neurology, and Radiology at Icahn School of Medicine at Mount Sinai, New York, conducted the first U.S. treatment in the ATHENA clinical trial. The ANA Funnel Catheter, designed for use during stent retriever-based thrombectomy, facilitates clot removal by restricting flow during retrieval, enabling simultaneous aspiration, and reducing the risk of clot fragmentation at capture. It features the largest capture diameter currently available for neuroendovascular thrombectomy.
Feasibility studies conducted with the device demonstrated high rates of reperfusion and first-pass success, along with a strong safety profile. However, the specific findings from these studies have yet to be published. The ATHENA IDE study, for which the company received IDE approval from the U.S. Food and Drug Administration in September 2024, is expected to complete enrollment in the first half of 2026.
Stroke remains one of the top three leading causes of death and the primary cause of serious long-term disability. One in four people over age 25 will have a stroke in their lifetime, with about 87% of cases classified as ischemic events caused by emboli or thrombotic occlusions in the neurovasculature. As the number of people experiencing stroke is expected to rise significantly, with a 34% increase in events projected by 2035, advancements in stroke treatment, such as the ATHENA trial, are of critical importance.
It is worth noting that the context or focus of the "Medical Device Manufacturing News" and "Medical Device Manufacturing Insights" articles are not revealed in the provided text. For the most up-to-date and detailed information on the progress or key findings of the ATHENA clinical trial, checking Anaconda Biomed’s official communications or clinical trial registries might be necessary. The identity of the new CEO of Anaconda Biomed has not been specified in the provided text.
Science and neurological disorders intersect as the ATHENA clinical trial, conducted by Anaconda Biomed, tests a novel medical-condition treatment for stroke victims. This trial explores therapies-and-treatments that focus on health-and-wellness, specifically in relation to managing ischemic events and reducing the risk of disability caused by stroke.
